Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, Abou‐Alfa G. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines. The Oncologist 2020, 26: e316-e326. PMID: 33021006, PMCID: PMC7873330, DOI: 10.1002/onco.13552.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBile Duct NeoplasmsBile Ducts, IntrahepaticHumansMorpholinesPyrimidinesPyrrolesQuality of LifeReceptors, Fibroblast Growth FactorConceptsSelective FGFR inhibitorsAdverse eventsDermatologic adverse eventsTyrosine kinaseFibroblast growth factor receptor tyrosine kinaseFGFR inhibitorsBladder cancerGrowth factor receptor tyrosine kinaseSkin eventsReceptor tyrosine kinasesPalmar-plantar erythrodysesthesia syndromeSelective fibroblast growth factor receptor (FGFR) inhibitorFibroblast growth factor receptor inhibitorManagement guidelinesGrowth factor receptor inhibitorsSkin adverse eventsTypical adverse eventsFrequent adverse eventsPossible adverse eventsEffective treatment strategiesBiological functionsEffective management plansQuality of lifeDermatologic eventsFGFR fusions